Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $8
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $9.2 to $8.
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $9.2 to $8.